Shares of Marseilles, France-based Innate Pharma SA took a hit recently after making known the adjustment of its lucrative deal with Astrazeneca plc for monalizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), but opinions are divided on what it means.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Achieve, AKL, Astellas, Direct Biologics, Kezar, Lilly, Merck, Merck KGaA, Oncologie, Roche.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Apnimed, Epygenix, Intensity, Mimedx, Novartis, Octapharma, Principia, Rhovac, Rigel, Virometix.

A new randomized controlled trial (RCT) of COVID-19 convalescent plasma (CCP) treatment for moderately ill COVID-19 patients run at 39 Indian hospitals found no association between CCP therapy and reduced mortality or progression to severe disease.

The positive interim 24-week liver biopsy results from Arrowhead Pharmaceuticals Inc.’s open-label phase II of its RNAi-based liver-targeted therapeutic, ARO-AAT, came as a surprise to the developers.

DUBLIN – Adrenomed AG reported its anti-adrenomedullin antibody, adrecizumab, attained an absolute reduction of 9% in mortality as compared with placebo at both 14 and 28 days (D28) after treatment in a phase II trial in a large subgroup of patients with septic shock.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adrenomed, Aim Immunotech, Algernon, Arcutis, Arena, Arrowhead, Aveo, Eli Lilly, Exicure, Galera, Genelux, Heron, Horizon, Immune-Onc, Knopp, Menarini, Ryvu, Springworks, Verastem, Verona.

HONG KONG – Interim results of a phase I study CT-P59, an anti-COVID-19 monoclonal antibody being developed by Incheon, South Korea-based Celltrion Inc., have confirmed the candidate’s safety, tolerability and pharmacokinetics in healthy subjects, giving the company confidence to ramp up production of the experimental antiviral.